Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ctDNA shows clinical value in advanced breast cancer

Publish date:: December 26, 2019

Key clinical point: The high accuracy and efficiency of circulating tumor DNA (ctDNA) testing allows for routine clinical use in advanced breast cancer.

Major finding: Gene level agreement between ctDNA results based on digital PCR versus sequencing was as high as 99.4%.

Study details: The plasmaMATCH trial is a parallel cohort trial; the present analysis involved 142 patients with advanced breast cancer.

Disclosures: The investigators disclosed relationships with Puma Biotechnology, AstraZeneca, Guardant Health, and Bio-Rad.

Citation:

Turner et al. SABCS. 2019 Dec 12. Abstract GS3-06.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,